Eden Review: GLP-1 Telehealth Provider Assessment

Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Eden Review is a telehealth platform that connects patients with healthcare providers for GLP-1 prescriptions, including semaglutide and tirzepatide options. The platform operates on a subscription or per-visit model, positioning itself as an accessible entry point for weight management and metabolic health consultations conducted remotely.

Choosing a GLP-1 provider involves more than platform reputation—it requires understanding medication sourcing, clinical oversight quality, and whether the provider's approach supports your personalized health goals. PlexusDx prioritizes compounded medications from licensed 503A pharmacies and optional genetic testing to contextualize your pathway responsiveness during provider conversations.

What Eden Review Offers in the Telehealth GLP-1 Space

Eden Review operates as a digital-first clinic connecting patients to licensed healthcare providers for GLP-1 consultations and prescription management. The platform emphasizes convenience, typically offering video visits within hours or days, membership tiers with variable pricing, and ongoing virtual follow-up care monitoring.

The platform's model appeals to patients seeking rapid access without geography-based clinic barriers. However, medication sourcing (whether branded, compounded from 503A, or compounded from 503B facilities) and prescriber credentialing standards vary. Patients should verify whether Eden partners with licensed 503A compounding pharmacies, 503B manufacturers, or primarily dispenses branded products like Ozempic, Wegovy, or Mounjaro.

Clinical Safety & Provider Credentialing Framework

A credible GLP-1 provider—whether through Eden Review or direct clinics—should conduct baseline screening including metabolic history, cardiovascular risk assessment, family history of thyroid cancer, and contraindication review. Reputable platforms document initial consultation depth, follow-up frequency, and monitoring protocols for adverse effects like nausea, pancreatitis risk markers, or gallbladder concerns.

Eden Review's clinical safety depends on prescriber qualifications (MD, NP, PA licensure verification), protocol documentation, and medication interaction screening. Patients should ask whether Eden requires baseline labs, tracks vitals during treatment, and escalates care to specialists when needed. The absence of structured follow-up protocols is a red flag across any telehealth GLP-1 provider.

Evaluation Factor	What to Verify
Provider Credentials	Licensed MD, NP, or PA with GLP-1 prescribing experience; board certification preferred
Medication Sourcing	Licensed 503A compounding pharmacy partnership, or branded pharmaceutical verification
Initial Screening	Metabolic labs, cardiovascular history, contraindication review, thyroid cancer risk assessment
Follow-Up Protocol	Scheduled check-ins, side-effect monitoring, dose adjustment guidelines, specialist referral pathways

Medication Sourcing: Branded vs. Compounded GLP-1 Options

Eden Review's medication options influence cost, quality assurance, and regulatory oversight. Branded GLP-1s (Ozempic, Wegovy, Mounjaro, Zepbound) carry FDA approval and manufacturer quality controls but may have higher out-of-pocket costs or insurance barriers. Compounded GLP-1s from licensed 503A pharmacies offer lower price points and physician flexibility but require transparency about compounding standards and potency verification.

Ask Eden Review directly: Does the platform partner exclusively with 503A compounding pharmacies, or does it also source from 503B manufacturers? Are compounded medications potency-tested? What quality assurance processes are documented? PlexusDx exclusively sources from licensed 503A compounding pharmacies, ensuring each prescription is made-to-order with transparent sourcing and quality oversight.

Cost, Insurance, and Access Transparency

Eden Review's pricing model typically includes subscription fees (ranging from monthly memberships to per-visit costs) plus medication expenses. Transparency about total out-of-pocket cost is essential—some platforms bundle provider visits and medications; others charge separately. Insurance acceptance varies, and many telehealth GLP-1 services operate as cash-pay options with limited insurance coordination.

Compare Eden Review's total cost against other telehealth providers and direct-clinic options. Ask whether insurance claims are filed, if prior authorization is managed by the platform, and whether medication costs are transparent upfront. PlexusDx compounded GLP-1 injections start at $149 monthly, with oral options from $209 monthly, allowing cost comparison alongside provider fees.

Genetic Pathway Context and Personalized Response

Individual differences in GLP-1 medication response are influenced by genetic variants in peptide signaling pathways (GLP1R, GIPR, FTO, MC4R). While no genetic test predicts exact medication response, pathway genotyping may help contextualize your predispositions during provider conversations, informing dose strategy or medication selection rationale.

PlexusDx offers the Precision Peptide Genetic Test ($99 add-on, $298 standalone) that reveals pathway variants associated with peptide metabolism and response patterns. This information is designed to support provider conversations about personalized dosing or medication choice—not as a standalone prediction tool. Eden Review does not currently offer genetic pathway testing, making external assessment an option for patients seeking additional personalization layers.

How PlexusDx Supports a More Personalized Approach

Genetic variation in peptide signaling pathways (GLP1R, GIPR, FTO, MC4R variants) influences how individuals metabolize and respond to GLP-1 medications. Knowing your pathway genotype may help contextualize response patterns and inform provider discussions about optimal dosing or medication selection.

The PlexusDx Precision Peptide Genetic Test reveals your predispositions in peptide genetic pathways, designed to support a more informed conversation with your healthcare provider. This test does not guarantee medication response or outcome; rather, it provides genetic context that qualified providers can interpret alongside clinical assessment, lifestyle, and medical history.

Whether you choose Eden Review or another GLP-1 provider, combining clinical evaluation with optional genetic pathway insight may strengthen your personalization strategy. PlexusDx supports this approach through both compounded GLP-1 medications and genetic testing, enabling deeper provider conversations about your individual pathway responsiveness.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is Eden Review and how does it operate as a GLP-1 provider?

Eden Review is a telehealth platform connecting patients with licensed healthcare providers for GLP-1 consultations and prescriptions. It operates on membership or per-visit pricing, offering rapid provider access and virtual follow-up care for weight management and metabolic health.

Does Eden Review use compounded or branded GLP-1 medications?

Eden Review's medication sourcing (branded, 503A compounded, or 503B sourced) should be verified directly with the platform. Patients should confirm whether medications are dispensed from licensed 503A pharmacies and whether potency testing is documented.

How does PlexusDx compare to Eden Review in cost and sourcing?

PlexusDx offers compounded GLP-1 from licensed 503A pharmacies at $149/mo monthly, depending on medication and dose. Unlike Eden Review's bundled provider-plus-medication model, PlexusDx focuses medication pricing separately, allowing transparent cost comparison.

What safety screening should a GLP-1 provider conduct before prescribing?

Reputable providers, including Eden Review, should document baseline metabolic labs, cardiovascular history, thyroid cancer risk assessment, contraindication review, and structured follow-up protocols. Absence of these safeguards is a clinical red flag.

Can genetic pathway testing improve my GLP-1 provider conversations?

Yes. PlexusDx's Precision Peptide Genetic Test reveals pathway predispositions in GLP1R, GIPR, FTO, and MC4R variants. This context may support provider discussions about personalized dosing, though it does not predict exact medication response.

Eden Review: Evaluating Telehealth GLP-1 Provider Quality & Clinical Safety